FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081062034> ?p ?o ?g. }

• W2081062034 endingPage "1210" @default.
• W2081062034 startingPage "1200" @default.
• W2081062034 abstract "ABSTRACT Limited information is available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters driving the efficacy of antimalarial drugs. Our objective in this study was to determine dose-response relationships of a panel of related spiroindolone analogs and identify the PK-PD index that correlates best with the efficacy of KAE609, a selected class representative. The dose-response efficacy studies were conducted in the Plasmodium berghei murine malaria model, and the relationship between dose and efficacy (i.e., reduction in parasitemia) was examined. All spiroindolone analogs studied displayed a maximum reduction in parasitemia, with 90% effective dose (ED 90 ) values ranging between 6 and 38 mg/kg of body weight. Further, dose fractionation studies were conducted for KAE609, and the relationship between PK-PD indices and efficacy was analyzed. The PK-PD indices were calculated using the in vitro potency against P. berghei (2× the 99% inhibitory concentration [IC 99 ]) as a threshold (TRE). The percentage of the time in which KAE609 plasma concentrations remained at >2× the IC 99 within 48 h (% T >TRE ) and the area under the concentration-time curve from 0 to 48 h (AUC 0–48 )/TRE ratio correlated well with parasite reduction ( R 2 = 0.97 and 0.95, respectively) but less so for the maximum concentration of drug in serum ( C max )/TRE ratio ( R 2 = 0.88). The present results suggest that for KAE609 and, supposedly, for its analogs, the dosing regimens covering a T >TRE of 100%, AUC 0–48 /TRE ratio of 587, and a C max /TRE ratio of 30 are likely to result in the maximum reduction in parasitemia in the P. berghei malaria mouse model. This information could be used to prioritize analogs within the same class of compounds and contribute to the design of efficacy studies, thereby facilitating early drug discovery and lead optimization programs." @default.
• W2081062034 created "2016-06-24" @default.
• W2081062034 creator A5002567037 @default.
• W2081062034 creator A5007366821 @default.
• W2081062034 creator A5012065320 @default.
• W2081062034 creator A5024405486 @default.
• W2081062034 creator A5027978440 @default.
• W2081062034 creator A5029774856 @default.
• W2081062034 creator A5036011732 @default.
• W2081062034 creator A5038323169 @default.
• W2081062034 creator A5039600726 @default.
• W2081062034 creator A5066817319 @default.
• W2081062034 creator A5077482907 @default.
• W2081062034 creator A5083068437 @default.
• W2081062034 date "2015-02-01" @default.
• W2081062034 modified "2023-09-26" @default.
• W2081062034 title "Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model" @default.
• W2081062034 cites W1902682915 @default.
• W2081062034 cites W1963527991 @default.
• W2081062034 cites W1966560405 @default.
• W2081062034 cites W1969503178 @default.
• W2081062034 cites W1973603244 @default.
• W2081062034 cites W1976010980 @default.
• W2081062034 cites W1982604624 @default.
• W2081062034 cites W1986363882 @default.
• W2081062034 cites W1992733039 @default.
• W2081062034 cites W2002651169 @default.
• W2081062034 cites W2014429457 @default.
• W2081062034 cites W2015251548 @default.
• W2081062034 cites W2019758371 @default.
• W2081062034 cites W2027630305 @default.
• W2081062034 cites W2029844797 @default.
• W2081062034 cites W2033634323 @default.
• W2081062034 cites W2038073476 @default.
• W2081062034 cites W2040713555 @default.
• W2081062034 cites W2046415190 @default.
• W2081062034 cites W2049789253 @default.
• W2081062034 cites W2050280954 @default.
• W2081062034 cites W2055098850 @default.
• W2081062034 cites W2061999977 @default.
• W2081062034 cites W2064093461 @default.
• W2081062034 cites W2079691262 @default.
• W2081062034 cites W2079901176 @default.
• W2081062034 cites W2080921958 @default.
• W2081062034 cites W2081321676 @default.
• W2081062034 cites W2082152486 @default.
• W2081062034 cites W2095554063 @default.
• W2081062034 cites W2098232887 @default.
• W2081062034 cites W2105668259 @default.
• W2081062034 cites W2113717321 @default.
• W2081062034 cites W2114583322 @default.
• W2081062034 cites W2116089057 @default.
• W2081062034 cites W2117175172 @default.
• W2081062034 cites W2119292094 @default.
• W2081062034 cites W2122816289 @default.
• W2081062034 cites W2135557679 @default.
• W2081062034 cites W2138717517 @default.
• W2081062034 cites W2139017151 @default.
• W2081062034 cites W2139876108 @default.
• W2081062034 cites W2143048218 @default.
• W2081062034 cites W2145336034 @default.
• W2081062034 cites W2146126520 @default.
• W2081062034 cites W2150760368 @default.
• W2081062034 cites W2154829613 @default.
• W2081062034 cites W2156465764 @default.
• W2081062034 cites W2157141899 @default.
• W2081062034 cites W2159056342 @default.
• W2081062034 cites W2161311583 @default.
• W2081062034 cites W2162398839 @default.
• W2081062034 cites W2166670458 @default.
• W2081062034 cites W2297954266 @default.
• W2081062034 cites W4233884518 @default.
• W2081062034 doi "https://doi.org/10.1128/aac.03274-14" @default.
• W2081062034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4335872" @default.
• W2081062034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25487807" @default.
• W2081062034 hasPublicationYear "2015" @default.
• W2081062034 type Work @default.
• W2081062034 sameAs 2081062034 @default.
• W2081062034 citedByCount "15" @default.
• W2081062034 countsByYear W20810620342015 @default.
• W2081062034 countsByYear W20810620342016 @default.
• W2081062034 countsByYear W20810620342017 @default.
• W2081062034 countsByYear W20810620342018 @default.
• W2081062034 countsByYear W20810620342019 @default.
• W2081062034 countsByYear W20810620342020 @default.
• W2081062034 countsByYear W20810620342021 @default.
• W2081062034 countsByYear W20810620342023 @default.
• W2081062034 crossrefType "journal-article" @default.
• W2081062034 hasAuthorship W2081062034A5002567037 @default.
• W2081062034 hasAuthorship W2081062034A5007366821 @default.
• W2081062034 hasAuthorship W2081062034A5012065320 @default.
• W2081062034 hasAuthorship W2081062034A5024405486 @default.
• W2081062034 hasAuthorship W2081062034A5027978440 @default.
• W2081062034 hasAuthorship W2081062034A5029774856 @default.
• W2081062034 hasAuthorship W2081062034A5036011732 @default.
• W2081062034 hasAuthorship W2081062034A5038323169 @default.
• W2081062034 hasAuthorship W2081062034A5039600726 @default.
• W2081062034 hasAuthorship W2081062034A5066817319 @default.

• next